FDA approves Pfizer's bivalent Covid booster for young children.

The FDA has authorized Pfizer's omicron booster shot for children aged six months to four years old who have previously received three doses of the company's original vaccine. The new bivalent shot targets both the original Covid strain and omicron BA.4 and BA.5. The decision was based on clinical trial data from 60 children who received the new booster, demonstrating an immune response to both strains. The authorization aims to better protect young children after a winter season that saw hospitals overwhelmed with respiratory illnesses, including Covid, RSV, and the flu.